Parmax Pharma Limited
BSE: PARMAX
Prev Close
36.42
Open Price
35.48
Volume
504
Today Low / High
34.5 / 36.8
52 WK Low / High
31.5 / 55.02
Range
35 - 39
The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 36.79, reflecting a change of 0.37 (1.01593%). The expected target range on the BSE is 35 - 39. The stock is showing an upward trend on the BSE, making it an appealing option for investors looking for growth in their portfolio.
Parmax Pharma Limited Graph
Parmax Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Parmax Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 36.79, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 36.79 | 37.16 | 33.44 - 40.87 |
| 37.53 | 30.02 - 45.03 | ||
| 37.89 | 26.53 - 49.26 | ||
| Bearish Scenario | 36.79 | 36.42 | 32.78 - 40.06 |
| 36.05 | 28.84 - 43.27 | ||
| 35.69 | 24.98 - 46.39 |
Overview of Parmax Pharma Limited
ISIN
INE240T01014
Industry
Medical - Pharmaceuticals
Vol.Avg
3,204
Market Cap
137,642,427
Last Dividend
0
Official Website
IPO Date
DCF Diff
76.46
DCF
-27
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 28.20 Cr | 21.54 Cr | 6.67 Cr | 0.2364 | 0.00 Cr | 0.00 Cr | -0.78 Cr | -2.09 Cr | -5.57 | -0.78 Cr | -0.0742 |
| 2024-03-31 | 11.05 Cr | 10.20 Cr | 0.86 Cr | 0.0776 | 0.00 Cr | 0.51 Cr | -4.65 Cr | -5.78 Cr | -34.73 | -3.42 Cr | -0.5228 |
| 2023-03-31 | 15.42 Cr | 8.83 Cr | 6.59 Cr | 0.4273 | 0.00 Cr | 0.73 Cr | 0.80 Cr | -0.10 Cr | -0.28 | 2.31 Cr | -0.0067 |
| 2022-03-31 | 18.25 Cr | 10.53 Cr | 7.72 Cr | 0.4228 | 0.00 Cr | 0.75 Cr | 1.03 Cr | 0.14 Cr | 0.38 | 2.59 Cr | 0.0078 |
| 2021-03-31 | 26.20 Cr | 17.45 Cr | 8.76 Cr | 0.3343 | 0.00 Cr | 0.71 Cr | 1.98 Cr | 0.75 Cr | 2.00 | 3.51 Cr | 0.0288 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.09 Cr | 18.75 Cr | 20.74 Cr | -1.9887 Cr | 7.70 Cr | 7.61 Cr | 3.31 Cr | 7.97 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 13.0375 Cr |
| 2024-03-31 | 0.05 Cr | 15.33 Cr | 15.26 Cr | 0.0709 Cr | 5.91 Cr | 5.86 Cr | 2.39 Cr | 9.38 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 9.2121 Cr |
| 2023-03-31 | 0.19 Cr | 17.61 Cr | 11.76 Cr | 5.8559 Cr | 5.37 Cr | 5.18 Cr | 4.31 Cr | 9.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 7.1366 Cr |
| 2022-03-31 | 0.84 Cr | 17.97 Cr | 12.01 Cr | 5.9599 Cr | 5.18 Cr | 4.34 Cr | 2.85 Cr | 10.44 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 7.3142 Cr |
| 2021-03-31 | 2.55 Cr | 22.73 Cr | 16.91 Cr | 5.8184 Cr | 5.89 Cr | 3.34 Cr | 3.95 Cr | 10.84 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 11.2455 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -0.6564 Cr | -0.7014 Cr | 1.3971 Cr | -1.3578 Cr | 0.0393 Cr | 0.0903 Cr | -0.7014 Cr | -2.0940 Cr | 1.7971 Cr | 0.0000 Cr | -0.9194 Cr |
| 2024-03-31 | -0.1901 Cr | -1.5869 Cr | 1.4274 Cr | -1.7770 Cr | -0.3496 Cr | 0.0572 Cr | -1.5869 Cr | -5.6559 Cr | 1.4274 Cr | 0.0000 Cr | 0.0000 Cr |
| 2023-03-31 | 0.3331 Cr | -0.9364 Cr | -0.0442 Cr | -0.6033 Cr | -0.6475 Cr | 0.4068 Cr | -0.9364 Cr | 0.0461 Cr | -0.0442 Cr | 0.0000 Cr | -1.4536 Cr |
| 2022-03-31 | 0.7494 Cr | -1.5316 Cr | -0.9100 Cr | -0.7822 Cr | -1.6922 Cr | 1.0543 Cr | -1.5316 Cr | 0.3033 Cr | -0.9100 Cr | 0.0000 Cr | 1.1006 Cr |
| 2021-03-31 | 3.5252 Cr | -3.1460 Cr | 0.3998 Cr | 0.3792 Cr | 0.7790 Cr | 2.7464 Cr | -3.1460 Cr | 1.2084 Cr | 0.3998 Cr | 0.0000 Cr | -1.2293 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4.83 Cr | 3.71 Cr | 1.12 Cr | 0.2313 | -0.39 Cr | -1.49 Cr | -3.98 | -1.56 Cr | -0.3098 |
| 2024-12-31 | 6.28 Cr | 4.56 Cr | 1.73 Cr | 0.2750 | -0.30 Cr | -0.39 Cr | -1.05 | 0.12 Cr | -0.0628 |
| 2024-09-30 | 9.28 Cr | 7.40 Cr | 1.87 Cr | 0.2019 | -0.20 Cr | -0.22 Cr | -0.58 | 0.32 Cr | -0.0234 |
| 2024-06-30 | 7.82 Cr | 5.87 Cr | 1.95 Cr | 0.2496 | 0.12 Cr | 0.01 Cr | 0.03 | 0.52 Cr | 0.0016 |
| 2024-03-31 | 4.26 Cr | 6.41 Cr | -2.15 Cr | -0.5050 | -0.78 Cr | -1.48 Cr | -5.12 | -0.89 Cr | -0.3473 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.09 Cr | 0.00 Cr | 0.09 Cr | 6.60 Cr | 3.31 Cr | 10.00 Cr | 7.97 Cr | 18.75 Cr | 20.74 Cr |
| 2024-09-30 | 0.08 Cr | 0.00 Cr | 0.08 Cr | 2.13 Cr | 2.72 Cr | 5.15 Cr | 10.01 Cr | 15.16 Cr | 15.26 Cr |
| 2024-03-31 | 0.05 Cr | 0.00 Cr | 0.05 Cr | 1.32 Cr | 2.39 Cr | 5.77 Cr | 9.38 Cr | 15.33 Cr | 15.26 Cr |
| 2023-09-30 | 0.14 Cr | 0.00 Cr | 0.14 Cr | 1.10 Cr | 2.39 Cr | 5.87 Cr | 9.11 Cr | 15.44 Cr | 12.25 Cr |
| 2023-03-31 | 0.19 Cr | 0.00 Cr | 0.19 Cr | 2.80 Cr | 4.31 Cr | 7.53 Cr | 9.50 Cr | 17.61 Cr | 11.76 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| No quarterly financial cash flow statement data available. | |||||||||
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Medical - Pharmaceuticals
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| MedPlus Health Services Limited | MEDPLUS | ₹821.25 | ₹98,339,283,675.00 | ₹72,992.00 |
Key Executives
Gender: Not Specified
Year Born: 1984
Gender: female
Year Born:
Gender: male
Year Born:
FAQs about Parmax Pharma Limited
The CEO is Umang Alkesh Gosalia.
The current price is ₹36.79.
The range is ₹31.5-55.02.
The market capitalization is ₹13.76 crores.
The P/E ratio is -6.60.
The company operates in the Healthcare sector.
Overview of Parmax Pharma Limited (ISIN: INE240T01014) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹13.76 crores and an average daily volume of 3,204 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.